CN103096887A - 用于抗微生物光动力疗法的糖取代的二羟基-二氢卟酚和β-官能化二氢卟酚 - Google Patents
用于抗微生物光动力疗法的糖取代的二羟基-二氢卟酚和β-官能化二氢卟酚 Download PDFInfo
- Publication number
- CN103096887A CN103096887A CN2011800386088A CN201180038608A CN103096887A CN 103096887 A CN103096887 A CN 103096887A CN 2011800386088 A CN2011800386088 A CN 2011800386088A CN 201180038608 A CN201180038608 A CN 201180038608A CN 103096887 A CN103096887 A CN 103096887A
- Authority
- CN
- China
- Prior art keywords
- carbohydrate
- substituent
- group
- benzyl ring
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000845 anti-microbial effect Effects 0.000 title abstract description 12
- 150000004035 chlorins Chemical class 0.000 title abstract description 4
- 238000002428 photodynamic therapy Methods 0.000 title description 16
- 239000004599 antimicrobial Substances 0.000 title description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 12
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims description 46
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 45
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims description 33
- 244000005700 microbiome Species 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 23
- 150000001720 carbohydrates Chemical class 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 230000008685 targeting Effects 0.000 claims description 17
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 108010038807 Oligopeptides Proteins 0.000 claims description 7
- 102000015636 Oligopeptides Human genes 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 125000003827 glycol group Chemical group 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 238000005286 illumination Methods 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 244000000010 microbial pathogen Species 0.000 abstract description 15
- 241000894006 Bacteria Species 0.000 abstract description 12
- 208000035473 Communicable disease Diseases 0.000 abstract description 7
- -1 serum Substances 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 150
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000003504 photosensitizing agent Substances 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 238000003756 stirring Methods 0.000 description 22
- 238000003818 flash chromatography Methods 0.000 description 18
- 238000009834 vaporization Methods 0.000 description 18
- 239000013078 crystal Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 16
- 238000001953 recrystallisation Methods 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 230000009849 deactivation Effects 0.000 description 15
- 150000004032 porphyrins Chemical class 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 150000001721 carbon Chemical group 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 241000192125 Firmicutes Species 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 241001597008 Nomeidae Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 235000010265 sodium sulphite Nutrition 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003989 dielectric material Substances 0.000 description 4
- 239000008241 heterogeneous mixture Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 0 *[C@](C=C(C1)C=CC1=C(*)C(*CCCC1)=C(*2)C2C1=C1*)C(CCCCCC2)=NC2=C(*)[C@@]2NC1=CC2 Chemical compound *[C@](C=C(C1)C=CC1=C(*)C(*CCCC1)=C(*2)C2C1=C1*)C(CCCCCC2)=NC2=C(*)[C@@]2NC1=CC2 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910021386 carbon form Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001663 electronic absorption spectrum Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004999 nitroaryl group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36671810P | 2010-07-22 | 2010-07-22 | |
US61/366,718 | 2011-07-22 | ||
PCT/US2011/045063 WO2013015774A1 (en) | 2011-07-22 | 2011-07-22 | Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103096887A true CN103096887A (zh) | 2013-05-08 |
CN103096887B CN103096887B (zh) | 2017-12-29 |
Family
ID=47006517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180038608.8A Expired - Fee Related CN103096887B (zh) | 2010-07-22 | 2011-07-22 | 用于抗微生物光动力疗法的糖取代的二羟基‑二氢卟酚和β‑官能化二氢卟酚 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9308185B2 (zh) |
EP (1) | EP2616065B1 (zh) |
CN (1) | CN103096887B (zh) |
BR (1) | BR112013001577B1 (zh) |
IL (1) | IL224380A (zh) |
MX (1) | MX352281B (zh) |
PL (1) | PL2616065T3 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6041360B2 (ja) * | 2011-07-22 | 2016-12-07 | バイオリテック ウンターネーメンスベタイリグンクス ツヴァイ アクツィエンゲゼルシャフト | 抗菌性光線力学療法のための、糖−置換ジヒドロキシ−クロリン及びβ−官能化クロリン |
US9156849B2 (en) * | 2011-08-12 | 2015-10-13 | Biolitec Pharma Marketing Ltd | Application of β-functionalized dihydroxy-chlorins for PDT |
CN103285403B (zh) * | 2013-06-21 | 2015-03-04 | 苏州大学 | 一种络合卟啉含糖光敏剂及其制备方法 |
EP3201201B1 (en) | 2014-09-30 | 2022-01-26 | biolitec unternehmensbeteiligungs II AG | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy |
US20210128935A1 (en) | 2015-07-28 | 2021-05-06 | Know Bio, Llc | Phototherapeutic light for treatment of pathogens |
EP3328491A4 (en) | 2015-07-28 | 2019-05-01 | PhotonMD, Inc. | SYSTEMS AND METHOD FOR THE LIGHT THERAPEUTIC MODULATION OF STICK OXIDE |
EP3210626A1 (en) | 2016-02-26 | 2017-08-30 | biolitec Unternehmensbeteiligungs II AG | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy |
US20220025185A1 (en) | 2018-12-10 | 2022-01-27 | Universitat Hamburg | Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy |
US12011611B2 (en) | 2020-03-19 | 2024-06-18 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11147984B2 (en) | 2020-03-19 | 2021-10-19 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11986666B2 (en) | 2020-03-19 | 2024-05-21 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11654294B2 (en) | 2021-03-15 | 2023-05-23 | Know Bio, Llc | Intranasal illumination devices |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005025A (en) * | 1959-08-07 | 1961-10-17 | American Cyanamid Co | Preparation of neutral chlortetracycline |
WO2003008430A2 (en) * | 2001-07-19 | 2003-01-30 | Institut Curie | Porphyrin derivatives for photodynamic therapy |
US20050259810A1 (en) * | 2004-05-18 | 2005-11-24 | Mark Cooke | Telephone NID isolation module |
WO2010033678A2 (en) * | 2008-09-18 | 2010-03-25 | Ceramoptec Industries, Inc. | Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2709491B1 (fr) * | 1993-09-03 | 1995-10-27 | Centre Nat Rech Scient | Nouveaux dérivés de porphyrines et leurs applications notamment en thérapeutique. |
JP2013532664A (ja) * | 2010-07-22 | 2013-08-19 | セラムオプテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | PDTのためのβ−官能化ジヒドロキシ−クロリンの用途 |
-
2011
- 2011-07-22 CN CN201180038608.8A patent/CN103096887B/zh not_active Expired - Fee Related
- 2011-07-22 BR BR112013001577-2A patent/BR112013001577B1/pt not_active IP Right Cessation
- 2011-07-22 MX MX2013000876A patent/MX352281B/es active IP Right Grant
- 2011-07-22 EP EP11869827.3A patent/EP2616065B1/en active Active
- 2011-07-22 PL PL11869827T patent/PL2616065T3/pl unknown
- 2011-07-22 US US13/189,113 patent/US9308185B2/en active Active
-
2013
- 2013-01-23 IL IL224380A patent/IL224380A/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005025A (en) * | 1959-08-07 | 1961-10-17 | American Cyanamid Co | Preparation of neutral chlortetracycline |
WO2003008430A2 (en) * | 2001-07-19 | 2003-01-30 | Institut Curie | Porphyrin derivatives for photodynamic therapy |
US20050259810A1 (en) * | 2004-05-18 | 2005-11-24 | Mark Cooke | Telephone NID isolation module |
WO2010033678A2 (en) * | 2008-09-18 | 2010-03-25 | Ceramoptec Industries, Inc. | Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt |
Also Published As
Publication number | Publication date |
---|---|
PL2616065T3 (pl) | 2018-05-30 |
BR112013001577A2 (pt) | 2017-12-12 |
CN103096887B (zh) | 2017-12-29 |
EP2616065B1 (en) | 2017-11-01 |
EP2616065A1 (en) | 2013-07-24 |
US9308185B2 (en) | 2016-04-12 |
MX2013000876A (es) | 2013-04-30 |
MX352281B (es) | 2017-11-16 |
BR112013001577B1 (pt) | 2021-05-04 |
EP2616065A4 (en) | 2014-05-14 |
IL224380A (en) | 2017-06-29 |
US20120263625A1 (en) | 2012-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103096887A (zh) | 用于抗微生物光动力疗法的糖取代的二羟基-二氢卟酚和β-官能化二氢卟酚 | |
Kustov et al. | Synthesis and investigation of novel chlorin sensitizers containing the myristic acid residue for antimicrobial photodynamic therapy | |
Zeng et al. | H2O2-responsive biodegradable nanomedicine for cancer-selective dual-modal imaging guided precise photodynamic therapy | |
Wang et al. | Aggregation-induced emission (AIE), life and health | |
Ma et al. | pH-responsive oxygen and hydrogen peroxide self-supplying nanosystem for photodynamic and chemodynamic therapy of wound infection | |
Tanaka et al. | Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils | |
Moreira et al. | An insight into the synthesis of cationic porphyrin-imidazole derivatives and their photodynamic inactivation efficiency against Escherichia coli | |
EP2526103B1 (en) | A process for the preparation of novel porphyrin derivatives and their use as pdt agents and fluorescence probes | |
Huang et al. | Antimicrobial photodynamic therapy with decacationic monoadducts and bisadducts of [70] fullerene: in vitro and in vivo studies | |
Xiao et al. | In vitro and in vivo demonstration of ultraefficient and broad-spectrum antibacterial agents for photodynamic antibacterial chemotherapy | |
JP2006515296A (ja) | 新規化合物およびその用途 | |
Zhdanova et al. | Synthesis and photodynamic antimicrobial activity of amphiphilic meso-arylporphyrins with pyridyl moieties | |
Santos et al. | Pyrazole-pyridinium porphyrins and chlorins as powerful photosensitizers for photoinactivation of planktonic and biofilm forms of E. coli | |
Zhou et al. | A new antibacterial nano-system based on hematoporphyrin-carboxymethyl chitosan conjugate for enhanced photostability and photodynamic activity | |
Özkan et al. | A [5] Rotaxane‐Based Photosensitizer for Photodynamic Therapy | |
Liu et al. | Emerging applications of aggregation‐induced emission luminogens in bacterial biofilm imaging and antibiofilm theranostics | |
Zhang et al. | Photodynamic and photothermal Ce6-modified gold nanorod as a potent alternative candidate for improved photoinactivation of bacteria | |
Ziental et al. | Zinc (II), palladium (II), and metal-free phthalocyanines bearing nipagin-functionalized substituents against Candida auris and selected multidrug-resistant microbes | |
CN103897691B (zh) | 细菌感染早期诊断的活体检测探针 | |
WO2013015774A1 (en) | Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy | |
Sowa et al. | Umbelliferone Decorated Water‐soluble Zinc (II) Phthalocyanines–In Vitro Phototoxic Antimicrobial Anti‐cancer Agents | |
Xu et al. | Highly hydrophilic quaternary ammonium salt containing organotin (IV) carboxylate for visualization of antibacterial action and multi-photon absorption activity | |
Atac et al. | Selective antibacterial and antibiofilm activity of chlorinated hemicyanine against gram-positive bacteria | |
Digby et al. | Highly potent photoinactivation of bacteria using a water-soluble, cell-permeable, DNA-binding photosensitizer | |
Huang et al. | Decacationic [70] fullerene approach for efficient photokilling of infectious bacteria and cancer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 61/366,718 2010.07.22 US False: 61/366,718 2011.07.22 US Number: 19 Volume: 29 |
|
CI02 | Correction of invention patent application |
Correction item: Priority Correct: 61/366,718 2010.07.22 US False: 61/366,718 2011.07.22 US Number: 19 Page: The title page Volume: 29 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY DATA; FROM: 61/366,718 2011.07.22 US TO: 61/366,718 2010.07.22 US |
|
RECT | Rectification | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160518 Address after: Austria Vienna Applicant after: FAIRFIELD INDUSTRIES Inc. Address before: Labuan Malaysia Applicant before: Bioltech Pharmaceutical Sales Co. Applicant before: Thera Moptek |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171229 |
|
CF01 | Termination of patent right due to non-payment of annual fee |